Characterization of 4-[ 18F]-ADAM as an imaging agent for SERT in non-human primate brain using PET: A dynamic study

Nuclear Medicine and Biology

Volumn 39, Issue 2, 2012, Pages 279-285

  Chen, Yu An ^a   Huang, Wen Sheng ^b   Lin, Yaoh Shiang ^b   Cheng, Cheng Yi ^b   Liu, Ren Shyan ^c   Wang, Shyh Jen ^d   Li, I Hsun ^b   Huang, San Yuan ^b   Shiue, Chyng Yann ^b   Chen, Cheng Yu ^b   Ma, Kuo Hsing ^a  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Biodistribution; Brain; Nonhuman primate or monkey; PET; Serotonin transporter; Transit time

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; FLUOXETINE; N,N DIMETHYL 2 (2 AMINO 4 FLUOROPHENYLTHIO)BENZYLAMINE F 18; RADIOPHARMACEUTICAL AGENT; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG; BENZYLAMINE DERIVATIVE; FLUORINE; N,N DIMETHYL 2 (2 AMINO 4 FLUOROPHENYLTHIO)BENZYLAMINE; N,N-DIMETHYL-2-(2-AMINO-4-FLUOROPHENYLTHIO)BENZYLAMINE; SEROTONIN RECEPTOR AFFECTING AGENT; SEROTONIN UPTAKE INHIBITOR;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; FEMALE; FRONTAL CORTEX; MACACA; MACACA CYCLOPIS; MALE; MESENCEPHALON; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY; THALAMUS; ANIMAL; BRAIN; METABOLISM; METHODOLOGY; REPRODUCIBILITY; SCINTISCANNING; TISSUE DISTRIBUTION;

ANIMALS; BENZYLAMINES; BRAIN; FEMALE; FLUORINE RADIOISOTOPES; FLUOXETINE; MACACA; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; POSITRON-EMISSION TOMOGRAPHY; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SEROTONIN AGENTS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; TISSUE DISTRIBUTION;

EID: 84856343269     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2011.08.002     Document Type: Article

References (33)

1. Kish S.J. How strong is the evidence that brain serotonin neurons are damaged in human users of ecstasy?. Pharmacol Biochem Behav 2002, 71:845-855.
2. Siegel A., Roeling T.A., Gregg T.R., Kruk M.R. Neuropharmacology of brain-stimulation-evoked aggression. Neurosci Biobehav Rev 1999, 23:359-389.
3. Mann J.J., Huang Y.Y., Underwood M.D., Kassir S.A., Oppenheim S., Kelly T.M., et al. A serotonin transporter gene promoter polymorphism (5-HTTLPR) and prefrontal cortical binding in major depression and suicide. Arch Gen Psychiatry 2000, 57:729-738.
4. Meltzer C.C., Smith G., DeKosky S.T., Pollock B.G., Mathis C.A., Moore R.Y., et al. Serotonin in aging, late-life depression, and Alzheimer's disease: the emerging role of functional imaging. Neuropsychopharmacology 1998, 18:407-430.
5. Pineyro G., Blier P. Autoregulation of serotonin neurons: role in antidepressant drug action. Pharmacol Rev 1999, 51:533-591.
6. Frazer A. Antidepressants. J Clin Psychiatry 1997, 58:9-25.
7. Nemeroff C.B., Owens M.J. Neuropharmacology of paroxetine. Psychopharmacol Bull 2003, 37:8-18.
8. Iversen L. Neurotransmitter transporters: fruitful targets for CNS drug discovery. Mol Psychiatry 2001, 5:357-362.
9. Hume S.P., Pascali C., Pike V.W., Turton D.R., Ahier R.G., Myers R., et al. Citalopram: labelling with carbon-11 and evaluation in rat as a potential radioligand for in vivo PET studies of 5-HT re-uptake sites. Int J Rad Appl Instrum B 1991, 18:339-351.
10. 11C]fluoxetine in a monkey brain. Nucl Med Biol 1995, 22:613-616.
11. Suehiro M., Wilson A.A., Scheffel U., Dannals R.F., Ravert H.T., Wagner H.N. Radiosynthesis and evaluation of N-(3-[18F]fluoropropyl)paroxetine as a radiotracer for in vivo labeling of serotonin uptake sites by PET. Int J Rad Appl Instrum B 1991, 18:791-796.
12. Elfving B., Madsen J., Knudsen G.M. Neuroimaging of the serotonin reuptake site requires high-affinity ligands. Synapse 2007, 61:882-888.
13. Szabo Z., Kao P.F., Scheffel U., Suehiro M., Mathews W.B., Ravert H.T., et al. Positron emission tomography imaging of serotonin transporters in the human brain using [11C](+)McN5652. Synapse 1995, 20:37-43.
14. Frankle W.G., Huang Y., Hwang D.R., Talbot P.S., Slifstein M., Van Heertum R., et al. Comparative evaluation of serotonin transporter radioligands 11C-DASB and 11C-McN 5652 in healthy humans. J Nucl Med 2004, 45:682-694.
15. Parsey R.V., Kegeles L.S., Hwang D.R., Simpson N., Abi-Dargham A., Mawlawi O., et al. In vivo quantification of brain serotonin transporters in humans using [11C]McN 5652. J Nucl Med 2000, 41:1465-1477.
16. Ginovart N., Wilson A.A., Meyer J.H., Hussey D., Houle S. Positron emission tomography quantification of [(11)C]-DASB binding to the human serotonin transporter: modeling strategies. J Cereb Blood Flow Metab 2001, 21:1342-1353.
17. Shiue G.G., Fang P., Shiue C.Y. Synthesis of N,N-dimethyl-2-(2-amino-4-[18F]fluorophenylthio)benzylamine as a serotonin transporter imaging agent. Appl Radiat Isot 2003, 58:183-191.
18. Ma K.H., Huang W.S., Kuo Y.Y., Peng C.J., Liou N.H., Liu R.S., et al. Validation of 4-[18F]-ADAM as a SERT imaging agent using micro-PET and autoradiography. Neuroimage 2009, 45:687-693.
19. Huang Y.Y., Ma K.H., Tseng T.W., Chou T.K., Ng H., Mirsalis J.C., et al. Biodistribution, toxicity and radiation dosimetry studies of the serotonin transporter radioligand 4-[18F]-ADAM in rats and monkeys. Eur J Nucl Med Mol Imaging 2010, 37:545-555.
20. Huang Y.Y., Huang W.S., Chu T.C., Shiue C.Y. An improved synthesis of 4-[18F]-ADAM, a potent serotonin transporter imaging agent. Appl Radiat Isot 2009, 67:1063-1067.
21. Szabo Z., McCann U.D., Wilson A.A., Scheffel U., Owonikoko T., Mathews W.B., et al. Comparison of (+)-(11)C-McN5652 and (11)C-DASB as serotonin transporter radioligands under various experimental conditions. J Nucl Med 2002, 43:678-692.
22. Ricaurte G.A., DeLanney L.E., Irwin I., Langston J.W. Toxic effects of MDMA on central serotonergic neurons in the primate: importance of route and frequency of drug administration. Brain Res 1988, 446:165-168.
23. Hatzidimitriou G., McCann U.D., Ricaurte G.A. Altered serotonin innervation patterns in the forebrain of monkeys treated with (+/-)3,4-methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery. J Neurosci 1999, 19:5096-5107.
24. Logan J. Graphical analysis of PET data applied to reversible and irreversible tracers. Nucl Med Biol 2000, 27:661-670.
25. Varnas K., Halldin C., Hall H. Autoradiographic distribution of serotonin transporters and receptor subtypes in human brain. Hum Brain Mapp 2004, 22:246-260.
26. Yokoyama C., Yamanaka H., Onoe K., Kawasaki A., Nagata H., Shirakami K., et al. Mapping of serotonin transporters by positron emission tomography with [(11)C]DASB in conscious common marmosets: comparison with rhesus monkeys. Synapse 2010, 64:594-601.
27. Laruelle M., Slifstein M., Huang Y. Relationships between radiotracer properties and image quality in molecular imaging of the brain with positron emission tomography. Mol Imaging Biol 2003, 5:363-375.
28. 11C]DASB: test-retest reproducibility using a multilinear reference tissue parametric imaging method. J Nucl Med 2006, 47:208-214.
29. Ogden R.T., Ojha A., Erlandsson K., Oquendo M.A., Mann J.J., Parsey R.V. In vivo quantification of serotonin transporters using [(11)C]DASB and positron emission tomography in humans: modeling considerations. J Cereb Blood Flow Metab 2007, 27:205-217.
30. Meyer J.H., Wilson A.A., Sagrati S., Hussey D., Carella A., Potter W.Z., et al. Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study. Am J Psychiatry 2001, 158:1843-1849.
31. Voineskos A.N., Wilson A.A., Boovariwala A., Sagrati S., Houle S., Rusjan P., et al. Serotonin transporter occupancy of high-dose selective serotonin reuptake inhibitors during major depressive disorder measured with [11C]DASB positron emission tomography. Psychopharmacology (Berl) 2007, 193:539-545.
32. Banks M.L., Czoty P.W., Gage H.D., Bounds M.C., Garg P.K., Garg S., et al. Effects of cocaine and MDMA self-administration on serotonin transporter availability in monkeys. Neuropsychopharmacology 2008, 33:219-225.
33. McCann U.D., Szabo Z., Vranesic M., Palermo M., Mathews W.B., Ravert H.T., et al. Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent (+/-)3,4-methylenedioxymethamphetamine ("ecstasy") users: relationship to cognitive performance. Psychopharmacology (Berl) 2008, 200:439-450.